Key result
Five-day remdesivir does not prolong the QTc interval in patients with severe COVID-19.
Why the study?
There is little information regarding the risk of drug-induced QT prolongation by remdesivir, an important FDA-approved COVID-19 therapy, which could provoke torsade de pointes and ventricular fibrillation.
Does intravenous remdesivir prolong the corrected QT interval in patients with severe COVID-19 disease?
Cohort (n=249)
No
Does intravenous remdesivir prolong the corrected QT interval in patients with severe COVID-19 disease?
In patients with severe COVID-19, a 5-day course of intravenous remdesivir was not associated with significant prolongation of the corrected QT interval.
Answers are grounded in this paper and cite their sources.
Short-course remdesivir was not associated with QTc prolongation; leaves open effects in higher-risk patients or with longer courses.
BACKGROUND: There is little information about the risk of drug-induced QT prolongation by remdesivir as the most important FDA approved anti COVID-19 drug. Prolongation of corrected QT interval (QTc) is considered as an indicator of an unfavorable outcome which may ultimately induce torsade de pointes and provoke ventricular fibrillation. The aim of this study was to determine the effects of remdesivir on QTc in patients with severe COVID 19 disease. METHODS: A historical cohort study was conducted on 249 patients who experienced severe COVID-19 disease and were candidate for treatment by intravenous remdesivir. We obtained a 12 lead electrocardiogram at the admission time and five days later to find any significant change in QTc and QT interval following therapy. We took blood samples at the time of hospitalization and then every day to determine the serum levels of electrolytes, complete blood count, fasting blood sugar (FBS), creatinine (Cr), and complete blood count. RESULTS: The results of this analysis showed blood pressure and heart rate (HR) were lower and total white blood cells and neutrophil counts, FBS and Cr levels were higher at fifth day than first day of study (P value < 0.001). Furthermore, QT interval was more prolonged at fifth day compared with beginning of remdesivir therapy (379.51 ± 34.90ms vs. 366.72 ± 30.97ms, P value < 0.001). However, QTc was not significantly increased at fifth day in comparison with first day (402.37 ± 33.62ms vs. 400.76 ± 30.18ms, P value = 0.524 by Bazett's formula and 402.81 ± 36.33 vs. 400.78 ± 32.49, P value = 0.459 by Fridericia's formula). CONCLUSIONS: The current study found no evidence linking the administration of remdesivir with prolongation of the QTc interval.
No takes yet. Share an insight, caveat, or question.
Saffar et al. (2024) conducted a cohort in Severe COVID-19 (n=249). Remdesivir vs. Baseline (pre-treatment) was evaluated on Corrected QT interval (QTc) by Bazett's formula at day 5 (p=0.524). Remdesivir administration for five days did not prolong the corrected QT interval compared to baseline in patients with severe COVID-19.
Synapse has enriched 10 related papers. Consider them for comparative context: